A pre-IND meeting is an FDA milestone meeting also known as Type B meeting . In these meetings the drug sponsor seeks FDA feedback about the quality, non- clinical and clinical development plan. The Pre-IND meetings are not mandatory.
View this resource Bookmark this resource
Pre Investigational New Drug (IND) interactions
Published by IRDiRC
Regulatory AffairsEarly Access SupportScientific AdviceMilestone MeetingPre-NDA MeetingPre Investigational New Drug Interaction